Corporate Governance Report

Chair’s Introduction

On behalf of the Board, I am pleased to present our Corporate Governance Report which explains how we applied our chosen framework the UK Corporate Governance Code 2024 (the ‘Code’), for the year ended 30 June 2026. This report details the strong governance, stakeholder engagement and a values-led culture that support our strategy and long-term value creation.

Purpose, Values and Culture
Our Purpose—to transform the business of healthcare through the profound impact our solutions deliver, enabling customers to provide quality care to their communities—guides our actions. Our independent position and broad offering of solutions and services in the revenue integrity and Business of Pharmacy, including 340B areas in the US healthcare market help providers deliver that care. We thank our colleagues for their continued commitment to this Purpose.

Our Purpose is supported by our core values, described in the ESG Statement in our 2026 Annual Report. The Board monitors the alignment of purpose, vision, strategy, values and culture. The Group recognises the importance of diversity and remains committed to attracting and nurturing diverse talent across gender, ethnicity, nationality, skills and experience.

Employee voice and engagement
Our people are central to our culture. The Board oversees their wellbeing, working arrangements, conditions and reward, and values the constructive feedback received through the engagement mechanisms described in this Report and the ESG Statement.

Section 172 and Stakeholder Engagement
We remain focused on considering stakeholder interests in Board decisions, as required under section 172 of the Companies Act 2006 and we outline our duties in the section 172 (1) statement and provide details of our engagement with stakeholders on pages 63 to 66 of our Annual Report for the year ended 30 June 2026 .

Environmental, Social and Governance (ESG)
Social impact is embedded in our Purpose. We support sustainability initiatives that benefit our stakeholders, communities and wider society.

Supported by the ESG Committee and broad employee participation, including through the Employee Advisory Group, there were various initiatives during the year (with some ongoing) across our three ESG Focus Areas. We also continue to voluntary disclose elements of Scope 3 emissions data collection to support baselining for net zero targets and climate risk management. Our ESG Statement and Non-Financial and Sustainability Information Statement, within our 2026 Annual Report, contain further details.

Board composition
The Board benefits from the Directors’ US healthcare experience, governance credentials and complementary skills. We thank David Kemp, who stepped down in November 2025, for his significant contributions including his insight and constructive challenge which were invaluable to the Board.

We also thank Alistair Erskine and Susan Nelson for assuming the responsibilities, from November 2025, as Senior Independent Director and as Chair of the Audit Committee respectively.

Board evaluation
Following the non-executive Director appointments during FY25, the Board completed an evaluation in early FY26. The overall conclusions were positive; the process is summarised later in this Report.

Annual General Meeting (‘AGM’)
The Board recognises that the AGM is an important event for all shareholders. The arrangements for the AGM, to be held in November 2026, are outlined in the Notice of AGM and we look forward to welcoming shareholders at the AGM.

Looking ahead
The Board notes the recent updates to the AIM Rules for Companies, effective from 5 August 2026, which include revised expectations for corporate governance reporting under AIM Rule 26 and remove the previous requirement for AIM companies to report against a recognised corporate governance code on a comply-or-explain basis. The Board remains committed to maintaining the highest standards of corporate governance, proportionate to Craneware’s size, stage of development and complexity, and is actively considering the updated guidance and disclosure requirements in determining the Group’s approach to corporate governance reporting for future reporting periods.

Thank you to our shareholders, employees and wider stakeholders for your continued support.

Dr Will Whitehorn OBE
Chair
20 September 2026

The Board follows the principles and those provisions of the UK Corporate Governance Code 2024 (the ‘Code’) which were applicable during FY26, in a manner proportionate to the Group’s size and nature. This Report explains how Craneware applied the Code’s principles, complied with its provisions and addressed any departures. The Code is available from the Financial Reporting Council at www.frc.org.uk. The Board acknowledges the revisions to the AIM Rules for Companies published in August 2026 and is considering relevant aspects of the revisions, including those within Rule 26 regarding corporate governance information and approach, from the year ending 30 June 2027

Overview: Application of the UK Corporate Governance Code 2024 (the “Code”) 

The Board is committed to governance that supports the Company’s purpose, long-term sustainable success and responsibilities to stakeholders and wider society. The Board is cognisant that the governance framework should be appropriate to the size and complexity of the Group and its operations. As a smaller company for Code purposes, Craneware explains below any Code provisions it considers disproportionate or less relevant for the Group.

Compliance statement
The Board has complied with the spirit of the UK Corporate Governance Code 2024 and applied the principles and complied with the provisions of the Code throughout the year ended 30 June 2026 (‘FY26’), with the exception of the following areas that the Board believes are not appropriate for a Group of our size:

  • Provision 17: due to the size of the Group, a separate nomination committee has not been established. Instead, these duties have been fulfilled by the Board as a whole.
  • Provision 36: Craneware does not have a formal post-employment shareholding policy for executive Directors. The Remuneration Committee keeps this under review. Existing shareholding guidelines for executive Directors and senior management, together with post-vesting holding periods for Long Term Incentive awards granted since October 2020, promote long-term alignment with shareholders.
  • Two elements of Provision 41: As an AIM company, Craneware is not required to comply with the Directors’ Remuneration Report regulations, but applies Provision 41 where proportionate and publishes a Remuneration Committee Report on pages 93 to 108 of the Annual Report and Financial Statements for the year ended 30 June 2026 (the ‘2026 Annual Report’). There was no specific employee engagement on executive Director remuneration during FY26; however, the Group’s median-pay positioning policy applies across the organisation.

The Remuneration Committee Report does not separately present the internal and external measures used to review executive remuneration. External measures informed the independent FY24 benchmarking study, and the Committee continues to monitor both appropriate internal and external measures. No changes were made to executive Directors’ base salaries or executive Director remuneration policy in FY26.

In accordance with AIM Rule 26, corporate governance information, including details of the Company’s corporate governance approach and explanations, are made within this section of the Company’s website.

Board Leadership and Company Purpose

The role of the Board
The Board is primarily responsible for the overall conduct of the Group’s business and for promoting the long-term success of the Group. The Board is collectively accountable to shareholders for the Group’s proper management. The Board must balance this responsibility with ensuring that the Directors have regard for key stakeholders and that there is sufficient time, information and understanding to properly take into account those stakeholders’ interests when making decisions and considering their long-term implications. The Board recognises that effective engagement with key stakeholders is a core component of long-term sustainability and success. Stakeholder Engagement information is set out on pages 63 to 66 the 2026 Annual Report. The Directors consider, both individually and collectively, that they have taken the factors, set out in s172(1)(a) to (f) of the Companies Act 2006, into account when exercising their duty to promote the success of the Group and of the Company during the year. The Board’s Section 172(1) Statement is on pages 57 to 62 of the 2026 Annual Report and it includes examples of how those matters have been considered in significant decisions of the Board.

The Board delegates day-to-day management to the Chief Executive Officer and the Operations Board under defined delegated authorities. Chaired by the Chief Executive Officer, the Operations Board comprises the Chief Financial Officer, Chief People Officer and six other members of the senior management team who collectively have the qualifications and experience necessary for the operations of the Group.

The governance structure is summarised below. A summary of the Operations Board’s sub-committees is provided on pages 23 and 24 of the 2026 Annual Report.

Governance Structure

Purpose, vision, strategy, values and culture
The Board establishes the Group’s purpose, vision, strategy and values, and oversees their implementation. The Board provides leadership for the Group and applies a governance framework to ensure that this is delivered effectively with appropriate control mechanisms.

Our Purpose is to transform the business of healthcare through the profound impact our solutions deliver, enabling our customers to provide quality care to their communities. Our purpose underpins our strategic initiatives and culture. The Board assesses and monitors the Group’s culture through ongoing engagement with management and other colleagues to ensure that its policies, practices and behaviours are aligned with the Group’s purpose, vision, strategy and values. Employee engagement mechanisms are referred to below within the ‘Stakeholder Engagement’ section.

The Board is responsible for delivering value for shareholders by setting the Group’s strategy and overseeing its implementation by the Operations Board. Our strategy and business model are described on pages 10 to 19 of the 2026 Annual Report. At least annually, the Board reviews the Group’s strategy, drawing on the wide and varied experience of the Board members (as outlined below within the ‘Composition of the Board’ section), including detailed US healthcare sector knowledge. The Board regularly monitors progress and trading performance.

There is a formal schedule of matters reserved for the Board which includes strategy, business plans, acquisitions and disposals, external reporting, significant financing and capital expenditure. It also defines levels of devolved decision making authority to the Operations Board.

Board Composition and Division of Responsibilities 

Board of Directors
During FY26, David Kemp stepped down from the Board on 21 November 2025 following the conclusion of the Company’s Annual General Meeting (‘AGM’) held on that date. Therefore, from 21 November 2025 to the date of this Report, the Board comprised the Chair, Will Whitehorn; executive Directors Keith Neilson, Craig Preston and Issy Urquhart; and independent non-executive Directors Alistair Erskine, Anne McCune, Tamra Minnier and Susan Nelson. The biographies of the Directors are on pages 68 and 69 of the 2026 Annual Report.

A summary of the composition of the Board in the year ended 30 June 2026 is:

Period

Composition of the Board

 

Chair

(Independent on Appointment)

Executive Directors

Independent^ Non-executive Directors

From 1 July 2025 to 21 November 2025

1

3

5

From 21 November 2025 to 30 June 2026
(and until the date of approval of this report)

1

3

4

^The Board considers that all of the non-executive directors are independent in character and judgement

In November 2025, responsibility for the Company Secretary role transferred from the Chief Financial Officer, who had previously held joint responsibility for the role, to Jill Goldsmith, who was appointed as Company Secretary.  The Board considers this change to be consistent with the Code’s emphasis on clear division of responsibilities, appropriate governance resources and effective procedures to support the Board in the discharge of its duties.

The Composition of the Board
The Board regularly reviews its composition and that of its committees, considering independence, skills, knowledge, experience and diversity. The composition of the Board has been designed to give a good range and balance of different skills and expertise, including significant experience in:

  • healthcare sector;
  • high growth companies;
  • software sector and analytics;
  • entrepreneurial cultures;
  • senior financial reporting;
  • strategic and operational human resource management;
  • both UK and US companies;
  • acquisitions;
  • integration of acquired businesses; and
  • other listed companies.

Through this mix of experience and skills, the Board and the individual Directors are well positioned to define the strategic aims of the Company as well as promote the Group’s values and standards throughout the organisation, whilst remaining focused on their responsibilities to shareholders and meeting their statutory obligations.

Throughout FY26, at least half the Board, excluding the Chair, comprised independent non-executive Directors. The Board assesses annually the independence of each non-executive Director. In making this assessment, in addition to considering Provision 10 of the Code, the Board determines whether the Director is independent in character and judgement and whether there are relationships or circumstances which are likely to affect, or could appear to affect, the Director’s judgement.

In regard to all of the non-executive Directors, the Board has not identified any matters that would affect their independence; the Board considers that all of the non-executive Directors are independent in character and judgement and free from any business or other relationship that could materially interfere with exercising that judgement. The Board acknowledges the factors contained in Provision 10 of the Code. The Board keeps the composition of the Board and its committees under review, including its continued independent balance.

Board of Directors as at 30 June 2026:

Board of Directors 2026

Division of Responsibilities
The Board has established clearly defined and well understood roles for the Chair of the Company and the Chief Executive Officer. A summary of the main responsibilities of these roles, and also that of the Senior Independent Director, is contained in the table below.

Role

Summary of Responsibilities

Chair

The Chair leads the Board, ensuring it operates effectively in directing the Company and the Group, and setting its agenda. The Chair is also responsible for upholding high standards of corporate governance and for promoting a culture of openness and debate, facilitating constructive Board relations and encouraging the effective contribution of all Non-Executive Directors to provide constructive support and challenge to the executive Directors and senior management. The Chair ensures that the Board receives accurate, timely and clear information. In addition, the Chair ensures that the Board is aware of the views of shareholders and other stakeholders.

Chief Executive Officer (“CEO”)

The Chief Executive Officer is accountable for delivering the strategic and financial objectives agreed by the Board and for ensuring the effective implementation of the Board’s decisions. The CEO chairs the Operations Board which manages, within delegated authority, the Group’s operations, in an ethical and sustainable manner and aligned to the Group’s culture. The CEO is also responsible for maintaining an effective framework of internal controls and risk management in addition to leadership of senior management.

Senior Independent Director

The Senior Independent Director provides a sounding board for the Chair, in addition to supporting governance matters, as well as providing an additional channel of contact for shareholders, other Directors or employees, if the need arises.

The Chair
Will Whitehorn was appointed Chair of the Board on 1 January 2020 and was independent on appointment, in accordance with Provisions 9 and 10 of the Code.

Non-Executive Directors
David Kemp served as Senior Independent Director until 21 November 2025 following the conclusion of the Company’s AGM held on that date. From that time, the Board appointed Alistair Erskine as Senior Independent Director.

The non-executive Directors assist in the development of strategy and monitor its delivery within the Company’s established risk appetite (as outlined in the Principal Risks and Uncertainties section of the Strategic Report in the 2026 Annual Report). They are responsible for bringing sound judgement and objectivity to the Board’s deliberations and decision-making process. In addition, the non-executive Directors constructively challenge, support and review the performance of executive Directors. As Board committee members the non-executive Directors also, amongst other matters within the terms of reference of each committee, review the integrity of the Group’s financial information, oversee the relationship with the external auditors, and set the remuneration of the executive Directors.

In addition to matters outlined above, there is regular communication between executive and non-executive Directors including, where appropriate, updates on matters requiring attention prior to the next Board meeting. The non-executive Directors meet, as appropriate but no less than annually, without executive Directors being present and further meet annually without the Chair present.

The non-executive Director contracts are available for inspection at the Company’s registered office and are made available for inspection both before and during the Company’s Annual General Meeting.

Committees of the Board of Directors
The Board has established an Audit Committee and a Remuneration Committee, details of which are provided below. The Board does not have a separate Nomination Committee as the Company has incorporated this function within the remit of the entire Board. Although not in compliance with Provision 17 of the Code, the Board considers this to be an appropriate arrangement in view of the size of the Group.

The Board keeps the composition of the Committees under review. The membership of both of the Committees during the year was as noted below.

Audit Committee members

Remuneration Committee members

From 1 July 2025 to 21 November 2025

David Kemp (Chair)

Anne McCune

Susan Nelson

Throughout the year ended 30 June 2026 (and up to the date of approval of this report)

Alistair Erskine (Chair)

Anne McCune

Tamra Minnier

From 21 November 2025  to 26 February 2026

Susan Nelson (Chair)

Anne McCune

From 26 February 2026 to 30 June 2026 (and up to the date of approval of this report)

Susan Nelson (Chair)

Anne McCune

Tamra Minnier

Attendance of Directors at scheduled Board and Committee meetings convened in the year, along with the number of meetings that they were invited to attend, are set out below:

Board

Remuneration Committee

Audit
Committee
No. Meetings in year112x3
Executive Directors
K Neilson11/11--
CT Preston11/11--
I Urquhart11/11--
Non-Executive Directors
W Whitehorn11/11--
A Erskine9/112/2-
A McCune10/112/22/3
T Minnier^10/112/21/1
S Nelson10/11-3/3
D Kemp*3/4-1/1

X in addition, a Remuneration Committee meeting was held in the first week of July 2026 (the first week of the new financial year) rather than before the end of FY26 – all members of the Committee attended that meeting but that meeting and the attendance is not included in this table.

^the membership of the Audit Committee changed during the year, the number of meetings attended is with reference to those while the non-executive Director was a member of each Committee.

*for this director, who stepped down from the Board during the year, the number of meetings attended is with reference to those until their date of resignation.

Where any Director has been unable to attend Board or Committee meetings during the year, their input has been provided to the Company Secretary ahead of the meeting. The relevant Chair then provides a detailed briefing along with the minutes of the meeting following its conclusion.

Board Appointments, Succession and Evaluation

Appointments to the Board
The Board regularly reviews its composition to maintain an appropriate balance of skills, experience, diversity and balance of independent non-executive Directors. For new appointments, the Board defines the skills, knowledge and experience required to add to the existing Board composition. A formal process is then undertaken, usually involving external recruitment agencies, with appropriate consideration being given, in regard to executive appointments, to internal and external candidates. Before undertaking the appointment of a Director, the Board establishes that the prospective candidate can give the time and commitment necessary to fulfil their duties, in terms of availability both to prepare for and attend meetings and to discuss matters at other times. This includes, prior to appointment, significant existing commitments being disclosed and assessed along with an indication of time commitment involved.

Conflicts of interest
Actual or potential conflicts are disclosed and assessed before Director appointment.  The Group has procedures in place for managing conflicts of interest and Directors have continuing obligations to update the Board on any changes to these conflicts. This process includes relevant disclosure at the beginning of each Board meeting. If any potential conflict of interest arises, the Articles of Association permit the Board to authorise the conflict, subject to such conditions or limitations as the Board may determine. The Board is satisfied that there is no compromise to the independence of, and nothing which would give rise to conflicts of interest for, any of the Directors who serve as directors on other company boards or who hold other external appointments.

Diversity
The Group is supportive of, and recognises the importance of diversity, including gender, ethnicity, nationality, skills and experience and professional, educational and socio-economic background. This is evident from the diverse, inclusive and breadth and depth of skills and experience within the Craneware team. The Board does not set specific targets but aims to ensure that the search process is sufficiently inclusive to encourage applications from diverse candidates with relevant skills, experience and knowledge with a fair and transparent selection process.

From 21 November 2025 to 30 June 2026 the Board comprised 50% female and 50% male directors. At the end of the financial year, across The Craneware Group, our team comprised 44% female, 55% male employees and 1% of employees not specifying gender (at 30 June 2025: 45% female, 54% male employees and 1% of employees not specifying gender). At Operations Board plus vice president level, the composition is approximately 38% female and 62% male (at 30 June 2025: 41% female and 59% male employees). Further information regarding Inclusive Excellence is contained within the ESG Statement on pages 49 and 50 of our 2026 Annual Report.

Commitment
All Directors recognise the need to allocate sufficient time to the Company for them to be able to meet their responsibilities as Board members. All non-executive Directors’ contracts include minimum time commitments; however, these are recognised to be the minimums.

Details of the other directorships held by each Board member are provided in the Directors’ biographies on pages 68 and 69 of the 2026 Annual Report. The Board has evaluated the time commitments required by these other roles and does not believe it affects their ability to perform their duties with the Company. Prior approval of the Board is required in advance of executive Directors undertaking external appointments. Since February 2024, I Urquhart has served as a non-executive director of Concurrent Technologies plc whose shares are listed on the AIM market of the London Stock Exchange. The other executive Directors do not hold any outside appointments with any other publicly traded company.

Succession Planning
The Board as a whole recognises its responsibility to ensure that appropriate plans are in place for orderly succession to the Board and has plans in place for any unforeseen circumstances regarding the executive Directors. The Board considers succession planning periodically, usually as part of its evaluation exercise. The composition of the Board has been carefully considered with these factors in mind.

The Board’s succession planning focused on leadership continuity, organisational risk and long-term talent development. The Group identified critical senior roles, assessed internal bench strength and readiness, and developed plans where no internal successor was identified. The Board reviewed senior-management succession and talent plans.

Development
The Chair is responsible for ensuring that all the Directors continually update their skills, their knowledge and familiarity with the Group in order to fulfil their role on the Board and the Board’s Committees. Updates dealing with changes in legislation and regulation and financial reporting requirements relevant to the Group’s business are provided to the Board by the Chief Executive Officer and the Chief Financial Officer and through the Board Committees by the Group’s external auditors and advisors.

All Directors have access to the advice and services of the Company Secretary, who is responsible for advising the Board on all governance matters, ensuring that Board procedures are properly complied with and that discussions and decisions are appropriately minuted. Directors may seek independent professional advice at the Company’s expense in furtherance of their duties as Directors. The Board ensures that the Audit and Remuneration Committees are provided with sufficient resources to undertake their duties.

Training in matters relevant to their role on the Board is available to all Directors. New Directors, who have not been employed within the Group prior to appointment, are provided with an induction in order to introduce them to the operations and management of the business. All new Directors receive a briefing on their role and duties as a director of a company which has its shares traded on AIM. This briefing is conducted by the Company’s advisers.

Information and Support
The Chair and Company Secretary set Board agendas with input from the Directors. Papers are circulated to the Directors in advance of Board meetings which contain appropriate detail regarding matters that will be covered, thereby encouraging openness and healthy debate at the meetings. The papers include, at minimum, Group financial results and reports from the Chief Executive Officer, Chief Financial Officer and Chief People Officer.

In addition, the non-executive Directors have access to, and correspond with, the Group’s Operations Board on an informal basis. This allows for better understanding of how the strategy set by the Board is being implemented across the Group.

As detailed in the Directors’ Report on page 73 of the 2026 Annual Report, the Company maintains appropriate insurance cover against legal action brought against Directors and officers. The Company has further indemnified all Directors or other officers against liability incurred by them in the execution or discharge of their duties or exercise of their powers.

Evaluation
Following the non-executive Director appointments during FY25, an evaluation began in early FY26 using a questionnaire completed by each Director. It covered the Chair and Board Committees; the Assistant Company Secretary at that time collated results for the Chair and the Board reviewed them. The Board concluded that its performance was satisfactory. A further evaluation process has begun in FY27. The results of this Board evaluation process will be considered by the Board in due course and then referenced in the FY27 Annual Report.

The Board will continue to consider the Code’s recommendation that the evaluation of the Board be carried out with an external evaluator at least every three years, however, at present, remains of the opinion that with the current size of the Board this is not required.

Re-election
The Company’s Articles of Association require at least one-third of eligible Directors to retire by rotation at each AGM and may be proposed for re-election. In addition, any Directors appointed or re-appointed three years or more prior to the AGM are required to retire from office and may be proposed for re-election. Such a retirement will count in obtaining the number required to retire at the AGM. New Directors, who were not appointed at the previous AGM, automatically retire at their first AGM and, if eligible, can seek re-appointment.

However, the Board recognises the Code’s recommendation that all Directors should stand for re-election every year, and whilst not a requirement, the Board has decided to adopt this recommendation as best practice.  As such, all Directors will retire from office at the Company’s forthcoming AGM. It is the intention of all Directors to stand for re-appointment.

In determining whether a Director, who wishes to stand for re-appointment, should be proposed for re-election at the 2026 AGM, the Board took into account each Director’s contribution to the Board’s effectiveness, which formed part of the Board evaluation. This review confirmed that all Directors continue to be effective and demonstrate commitment to their roles and so the Board recommended their re-appointment.

Stakeholder Engagement  

Shareholders

Dialogue with Shareholders
The Company communicates openly with institutional and private investors and responds promptly to queries.  In conjunction with the Company’s brokers and other financial advisors all relevant news is distributed timely through appropriate channels to ensure shareholders are able to access material information on the Company’s progress. To facilitate this:

  • All shareholders are invited to attend the AGM and encouraged to take the opportunity to ask questions.
  • The primary point of contact for shareholders on operational matters are Keith Neilson as Chief Executive Officer and Craig Preston as Chief Financial Officer.
  • The primary point of contact for shareholders on corporate governance and other related matters is Will Whitehorn as Chair. Alistair Erskine, as Senior Independent Director, is available as a point of contact should a shareholder not wish to contact the Chair for any reason.
  • The Board welcomes regular engagement with major shareholders to understand their views on governance and performance against our stated strategy.
  • The Chair ensures that the Board as a whole has a clear understanding of the views of shareholders.
  • The Board aims to ensure that both the investor and analyst communities understand our purpose, strategy, business model and financial and operational performance.

Keith Neilson and Craig Preston meet shareholders regularly, normally immediately following half-year and full-year results announcements, to discuss the Group’s performance and answer questions. The Board monitors the success of these meetings through anonymous shareholder and analyst feedback collected by the Company’s broker and financial PR adviser.

During the year, the Chair of the Board met with shareholders at their request. The Chair is available to answer questions and to meet with shareholders on request.

The Board receives questionnaires from some shareholders periodically in relation to ‘Environmental, Social and Governance’ (“ESG”) matters. These questionnaires are reviewed, with assistance from the ESG Committee, and then the questionnaires are completed and returned to the requestor.

This website has a section for investors that contains all publicly available financial information and news on the Company and the Group. Details of the Company’s share capital and substantial shareholders are contained in the Directors’ Report, within the 2026 Annual Report, on pages 73 to 75.

Constructive Use of General Meetings
The Board encourages shareholder participation at the AGM. The Notice of AGM together with all resolutions and explanations of the resolutions are sent at least 20 working days beforehand. Separate resolutions are proposed for substantially separate matters and specifically relating to the report and financial statements. All Directors, where possible, make themselves available to answer any questions from shareholders.

The voting on each Resolution tabled at the AGM can be conducted on a show of hands or by way of poll votes. Shareholders, if they are unable to attend the meeting in person, are strongly encouraged to participate in the AGM by voting by proxy ahead of the meeting. AGM voting results are published promptly, following the conclusion of the meeting, on the Company’s website.

If an AGM resolution receives 20% or more of votes cast against, the Board will consult with shareholders to understand the reason behind the result. Following the AGM that was held on 21 November 2025 the Company announced that all resolutions were passed and in respect of each resolution at least 80% of the proxy votes received were ‘for’ the resolutions proposed.

As required for the Reduction of Capital process (outlined in the Directors’ Report within the 2026 Annual Report), a general meeting of the Company was convened on 20 August 2025, following the Notice of General Meeting and Circular issued to shareholders on 1 August 2025. The resolutions to approve the capital reduction were voted on by shareholders, by way of a poll, at the general meeting and were duly approved.

Employee engagement
The Board uses alternative workforce engagement mechanisms instead of the three methods suggested by the Code. These engagement mechanisms include the initiatives described in the ESG Statement, within the 2026 Annual Report, on pages 49 to 53. The Board considers these engagement arrangements to be proportionate and effective, supported by the Chief People Officer and executive Director Issy Urquhart. The Board will continue to keep these engagement mechanisms, in addition to those for other stakeholders, under review to ensure that the engagement mechanisms are effective.

The Chief People Officer ensures that the Board receives regular reports about a range of factors and issues affecting our employees to ensure that appropriate consideration is given and early action taken where necessary. The Board oversees people strategy, plans, policies and practices, reviewing metrics such as retention and engagement, organisational culture updates and insights from onboarding and exit surveys.

Leadership Roundtables enable two-way discussion, between executive leaders and cross-functional groups of 8 to 10 employees with a range of roles, on topics such as culture, engagement, business performance and other matters of interest. When possible, a non-executive Director of the Company may chair the Roundtable.

Engagement with other key stakeholder groups
The ESG Statement, the Stakeholder Engagement section and the Directors’ Report within the 2026 Annual Report contain an overview of the engagement with other key stakeholder groups including: customers and the community, bank finance providers and suppliers.

ESG Committee
The ESG Committee is chaired by Issy Urquhart, Chief People Officer and executive Director. It is an Operations Board subcommittee overseen by the Board, which approved its terms of reference and receives regular updates. Further information regarding this Committee appears in the ESG Statement and the Non-Financial and Sustainability Information Statement sections of the 2026 Annual Report.

Audit, Risk and Internal Control

Chair of Audit Committee Introduction
I am pleased to report on the activities of the Committee, the first report since I assumed the role of Chair of the Audit Committee in November 2025 when David Kemp stepped down from the Board. We greatly appreciate the significant contributions, knowledge and guidance that David provided to the Committee. We were delighted to welcome Tamra Minnier (‘Tami’) as a member of the Committee from February 2026, particularly given the extensive senior executive experience in US healthcare that Tami brings to the Committee.

The Committee’s main focus throughout the year, and ongoing, is monitoring the integrity and transparency of the Group’s financial reporting. Our work is supported by the Group’s Finance team, the Risk and Compliance Committee and our external auditors, PricewaterhouseCoopers LLP.

I hope that you find this report helpful in understanding the work of the Committee and I welcome any feedback from shareholders in relation to the Committee and its activities.

Susan Nelson
Chair of the Audit Committee

Audit Committee and Auditors
The Board has established an Audit Committee, of independent non-executive directors, to assist the Board with the discharge of its responsibilities in relation to internal and external audits and controls. The membership of the Committee during the year is shown in the ‘Committees of the Board of Directors’ section above. The Chief Financial Officer and other senior management attend meetings by invitation and the Committee also meets the external auditors without management present. Susan Nelson, as chair of the Audit Committee, has recent and relevant financial experience and the Audit Committee as a whole has significant experience and competence in the US healthcare sector. The Audit Committee will normally meet at least twice a year; Committee meeting attendance in FY26 is noted in the ‘Committees of the Board of Directors’ section above.

The terms of reference of the Audit Committee are available here and at the Company’s registered office. Details of how the Audit Committee has discharged its responsibilities are provided below.

Financial and Business Reporting
The Board recognises its responsibilities, including those statutory responsibilities stated on page 76 of the 2026 Annual Report. An assessment of the Group’s market, business model and performance is presented in the Chair’s Statement and the Strategic Report on pages 8 to 19 of the 2026 Annual Report.

As detailed on page 72 of the Directors’ Report within the 2026 Annual Report, the Board has confirmed that it is appropriate to adopt the going concern basis in preparing the Consolidated and Company financial statements for the year ended 30 June 2026. The Board has explained within the Viability Statement section of the Strategic Report on page 33 of the 2026 Annual Report that it has assessed the prospects of the Company and the Group, taking into account the Group and the Company’s current financial position and principal risks, as well as compliance with debt finance covenants throughout the assessment period. In making this assessment, the Board has considered the cyber incident described in Note 25 (to the FY26 financial statements) and a range of potential financial outcomes.

Risk Management and Internal Control
Details of the principal risks and uncertainties and emerging risks facing the Group, along with a description of the Group’s risk management procedures, are detailed in the Strategic Report on pages 22 to 33 of the 2026 Annual Report. The principal financial risks are detailed in Note 3 to the financial statements for the year ended 30 June 2026.

The Directors are responsible for the Group’s internal control system, covering all material controls including: financial, operational and compliance controls which are reviewed annually for effectiveness by the Audit Committee and the Board. The Group’s system of internal control is designed to support the achievement of the Group’s business objectives by appropriately managing, rather than eliminating, the associated risks. As such, the controls can only provide reasonable, not absolute, assurance against material misstatement or loss. Given the nature of the Group’s business, there is a particular focus on data and cyber security and loss or misuse of data risks, as explained the Principal Risks and Uncertainties section of the 2026 Annual Report. The Audit Committee and Board’s review of Group’s risk management and internal control systems in FY26 included, but was not limited to; assessment of the operation of the risk management process and its outputs; the controls noted within the mitigations in the Principal Risks and Uncertainties section of the 2026 Annual Report; and consideration of the following elements.

Internal controls and risk management procedures are embedded in business processes and regularly assessed, supported by the Operations Board and its sub committees, as described on pages 22 to 24 of the 2026 Annual Report. Identified improvements are addressed by management and the Board, supported by the implementation of metrics and quality objectives. Oversight from the Transformation team continues to support the enhanced visibility of regularly updated metrics across the organisation.

The Board reviews and approves the annual financial forecast and receives, at least quarterly, financial and operational reporting, supplemented by monthly financial information. Forecasts are refreshed at least quarterly; significant variances and corrective actions are considered, discussed and monitored by the Board.

Authorisation for expenditure is governed by established approval thresholds which are cascaded through the management structure. Any expenditure exceeding pre-defined levels must be approved by the executive Directors and designated senior managers.

There is an extensive complement of policies and procedures, applicable across The Craneware Group, including: business ethics; information security; whistleblowing; anti-corruption, bribery and fraud; anti-slavery and human trafficking along with monitoring of mandatory employee training and policy acknowledgement for key areas. This is referred to in the ESG Statement section of the 2026 Annual Report.

Audit Committee: role, responsibilities and activities during the year

During FY26, operating under its published terms of reference (which are available here), the Audit Committee discharged its responsibilities, including the review and monitoridng of:

  • interim and annual reports information including consideration of the appropriateness of accounting policies and material assumptions and estimates adopted by management;
  • the integrity of the Annual Report and Financial Statements, the Interim Report and any formal announcements relating to financial performance, to ensure clarity and completeness of disclosures, including those relating to alternative performance measures (including adjusted performance measures);
  • developments in accounting and reporting requirements;
  • matters of accounting significance, estimation and judgement;
  • the unaudited condensed interim financial statements of the Company, for the six month period ended 31 December 2025, which were prepared for the purpose of s838 of the Companies Act 2006 and filed with the Registrar of Companies;
  • (along with the other directors) the information included in the Circular sent to shareholders in August 2025 for the Reduction of Capital process, as outlined in the Directors’ Report;
  • the systems of internal control and their effectiveness, reporting and making new recommendations to the Board on the results of the review and receiving regular updates on key risk areas of financial control;
  • oversight of the assessment and readiness, of the Company and the Group, for relevant provisions of the Economic Crime and Corporate Transparency Act 2023;
  • the adoption of the UK Corporate Governance Code 2024;
  • the requirements or otherwise for an internal audit function;
  • external auditors’ plan for the year-end audit of the Company and the Group;
  • the performance and independence of the external auditors. The auditors provide annually a letter to the Committee confirming their independence and stating the methods they employ to safeguard it;
  • the audit fees charged by the external auditors;
  • the formal engagement terms entered into with the external auditors;
  • the provision of tax compliance services to the Group;
  • the Committee’s effectiveness.

The Audit Committee reviewed the Group’s profitability and liquidity under forecast scenarios, incorporating the impact of the relevant aspects of the SaaS business model as well as a range of potential financial and operational consequences of the cyber incident described in Note 25 to the FY26 financial statements. As part of this assessment, the Committee has also reviewed the viability statement and going concern note (as included on page 33 and page 72 respectively of the 2026 Annual Report), following which it was agreed that the going concern basis of accounting continues to be an appropriate basis of preparation for the financial statements for the year ended 30 June 2026.

In accordance with its terms of reference, the Committee has reported to the Board as to how it has discharged its responsibilities throughout the year.

Significant matters considered in relation to the financial statements

The Audit Committee reviewed accounting policies, critical judgements and estimation uncertainty, considering reports from the Chief Financial Officer and external auditor. It concluded that the judgements and estimates met the required accounting and disclosure standards.

The following table sets out the significant areas considered by the Committee in relation to the Group’s financial statements for the year ended 30 June 2026, in particular the critical judgements and estimates of the Company as disclosed in the financial statements:

Area of judgement or estimate

Matter considered and Role of the Committee

Financial reporting implications of the cyber incident (Group and Company)

Refer to Note 25 to the financial statements for the year ended 30 June 2026. The incident required the Directors to assess the potential financial reporting implications and the nature and extent of disclosures required in the financial statements.  It was also required to consider the impact of the incident on going concern and in making the Viability Statement. Given the significance of the incident, the evolving nature of investigations and regulatory processes there was significant management judgement involved in assessing all of the above which had to be considered by the Audit Committee.

Impairment assessment

Goodwill and other intangible assets are significant amounts on the Group’s Balance Sheet. Tests have to be conducted annually whether Goodwill has suffered any impairment and for other assets, including acquired intangibles, at any point where there are indications of impairment. This requires an estimation of the recoverable amount of the applicable cash generating unit to which the Goodwill and other assets relate. Assessing the recoverable amount requires significant estimates of the expected future cash flows from the specific cash generating unit using certain key assumptions including growth rates and a discount rate and therefore the Committee reviews this assessment.

Revenue recognition (Group and Company), including compliance with IFRS 15

Revenue and deferred income are significant amounts in the context of the Consolidated Statement of Comprehensive Income and the Group and Company Balance Sheets respectively. The amount of revenue to be recognised and timing of revenue recognition are determined based on the details and terms contained in the contracts with customers.

Revenue recognition on non-standard contracts can involve significant judgement and interpretation of both the Group’s policy and IFRS 15.

Internally developed intangible assets (Group and Company)

The Group and the Company capitalise development costs when the conditions for capitalisation, as specified in the principal accounting policies within Note 1 to the FY26 financial statements, have been met. Consequently, the Directors are required to continually assess the commercial potential of each product in development and its useful life following launch. There is judgement involved in determining whether or not costs being capitalised meet the definition of intangible assets under IAS 38 Intangible assets. In addition, there may be judgement involved in the assessment of whether or not the intangible assets will generate future economic benefit sufficient to recover the carrying value of the intangible asset.

The Committee reviews this area as there is judgement involved in the Directors’ assessment.

 

The Group uses Alternative Performance Measures (“APMs”) and provides additional disclosures, including reconciliations to statutory measures, in Note 26 to the FY26 financial statements. The Committee considers it important to take account of both the statutory measures and the APMs when reviewing these financial statements. In particular, items excluded from underlying results were reviewed by the Committee and it is satisfied that the presentation of these items is clear, applied consistently across financial years and that the level of disclosure is appropriate.

The Audit Committee also reviewed and considered other matters during and in respect of the financial year ended 30 June 2026 including management’s assessment of new accounting standards that were not effective for adoption until after 30 June 2026.

The Audit Committee considered and discussed with the rest of the Board whether the Annual Report, taken as a whole is fair, balanced and understandable and provides the information necessary for stakeholders to assess the Group’s position and performance, business model and strategy.

Internal audit arrangements

The Committee has considered the arrangements for internal audit and concluded that a formal function was not required, in view of the Group’s current size, geographical dispersion, complexity and internal control environment. The Audit Committee believes that management is able to derive assurance regarding the adequacy and effectiveness of internal controls and risk management procedures, given the common enterprise resource planning system across the Group and also the close involvement of the Directors and the senior management on a day-to-day basis, without the need for an internal audit function.

Given the importance of procedures, security, regulatory compliance, and controls related to customer data and the Group’s solutions, assurance activities for Craneware are primarily concentrated on these areas. The Group has maintained HITRUST CSF r2 Certification for Trisus, InSight, corporate services and associated operational processes since 2019. This is an external, validated audit of Craneware’s security and data privacy practices, as described on pages 55 and 56 of the 2026 Annual Report. Full assessments occur every two years, with interim assessments in intervening years; a full assessment was completed in FY25. Trisus platform, InSight, Sentinel and Sentrex, Trisus Decision Support, Trisus Labor Productivity and Trisus Medication Inpatient Rebate applications meet American Institute of Certified Public Accountants (AICPA) Service Organization Controls (SOC) requirements, completing the external audit verified SOC2 Type II assessments annually. Sentinel and Sentrex also complete the external audit verified SOC1 Type II assessment annually. The Craneware Group engages with third party auditors to support effective security practices and compliance with appropriate regulations. We regularly evaluate to ensure our certification selections continue to be the best measure of security controls. Further details regarding information security are provided in the Principal Risks and Uncertainties section and in the ESG Statement of the 2026 Annual Report.

The Audit Committee will continue to monitor whether there is a requirement for an internal audit function and will report accordingly to the Board.

External audit

The Committee acknowledges the contents of the FRC’s Audit Committees and the External Audit: Minimum Standard and has taken relevant action to ensure it meets the minimum standard. Under its terms of reference, the Audit Committee is responsible for overseeing the relationship with the external auditors including monitoring their independence, objectivity and performance, and for making a recommendation to the Board regarding the appointment of external auditors on an annual basis. In making these recommendations the Committee considers the effectiveness of the audit process and quality of the audit which may include assessment of the:

  • experience, industry knowledge and expertise of the auditors;
  • scope and planning of the audit and the appropriateness of significant variations from the plan;
  • appropriate and effective use of specialists;
  • quality of the processes adopted;
  • auditors’ explanations of significant risks to audit quality by reference to the Group’s specific circumstances and changes to the risks and how these risks have been addressed;
  • level of audit fees;
  • audit team’s attitude to, and handling of, key audit judgements;
  • audit team’s ability to challenge and communicate effectively with management;
  • the audit firm’s quality assurance systems;
  • quality of the final report of the auditors to the Audit Committee;
  • FRC’s annual report on the auditors.

The Group’s external auditors, PricewaterhouseCoopers LLP, were first appointed as external auditors of the Company for the year ended 30 June 2003.

The Audit Committee conducted the most recent audit tender in FY21 and recommended PricewaterhouseCoopers LLP to the Board. The Board considered the Audit Committee’s recommendation and subsequently approved PricewaterhouseCoopers LLP for recommendation to shareholders, for re-appointment as auditors, at the Company’s AGM held in November 2021. This resolution was approved by the shareholders.

The audit partner within PricewaterhouseCoopers LLP is required to rotate every five years.  As reported in last year’s annual report, FY25 was the fifth year that the audit partner, Paul Cheshire, had led the engagement team for the audit of the Group’s financial statements. As such, Paul rotated off the audit engagement and a new audit partner, Craig Willis, took over as the lead engagement partner for financial year 2026.

Following the completion of PwC’s FY25 audit, the Committee was informed that the FRC’s Audit Quality Review (AQR) team had selected the audit of the Group’s FY25 financial statements for its review. The Audit Committee has received a copy of the AQR’s Inspection Report and was pleased to note that the AQR team did not identify any key or other findings arising from its inspection.

The Audit Committee reviewed and approved the external audit plan, in respect of the audit of the Company and Group’s FY26 financial statements, including the external auditors’ identification of the key audit risks, the planned scope of work, the audit timetable and also details of how the auditors have assessed their independence to be able to undertake the audit work. This audit plan was reviewed, along with the Committee’s assessment of the auditors’ independence, and was agreed in advance by the Audit Committee. Having considered the planning work carried out and the results of the audit of the Group and Company financial statements for the year ended 30 June 2026, the Committee was satisfied that the approach adopted was robust and appropriate and that auditor independence and objectivity could be relied upon. The Committee is satisfied with the performance of the external auditors and with the policies and procedures in place to maintain their objectivity and independence. The Committee considers that PricewaterhouseCoopers LLP possesses the skills and experience required to fulfil its duties effectively and efficiently and that the audit of the Group and Company financial statements for the year ended 30 June 2026 was effective. The Committee has therefore recommended to the Board the reappointment of PricewaterhouseCoopers LLP as the Company’s auditors at the forthcoming AGM of the Company.

Non-audit services provided by the external auditors
Craneware is an ‘Other Entity of Public Interest’ (“OEPI”) in accordance with the definition specified by the Financial Reporting Council and, consequently, the Company’s external auditors are only able to perform a limited number of assurance related non-audit services.

The Audit Committee has implemented procedures relating to the provision of non-audit services by the Company’s auditors (subject always to the limitations in respect of Craneware being an OEPI), which include non-audit work and any related fees over and above a de-minimis level to be approved in advance by the Chair of the Audit Committee.

During the year ended 30 June 2026, as was the case in the previous financial year, the Company’s auditors have not provided the Group or the Company with any non-audit work. Details of the fees paid to the auditors for audit services are shown in Note 5 to the financial statements for the year ended 30 June 2026.

Whistleblowing Policy
The Group is committed to conducting its business with honesty and integrity and it is expected that these high standards be upheld throughout the organisation. The Group has a Whistleblowing Policy as an element of fostering a supportive and open culture within the organisation and this is complemented by annual mandatory training for employees. This Policy includes arrangements by which employees, consultants or contractors may, in confidence and also anonymously should they wish, raise concerns regarding possible improprieties in matters of financial reporting or other matters. These concerns would then be investigated and followed up appropriately. The Board has oversight and provision to review these arrangements and any reports arising from their operation.

Remuneration

The Board has established a Remuneration Committee which comprises non-executive Directors all of whom the Board considers to be independent, as described within the ‘Composition of the Board’ section above. and the membership of this Committee throughout the financial year is set out in the ‘Committees of the Board of Directors’ section above.

The Remuneration Committee recommends to the Board executive Director remuneration packages and remuneration of the Chair of the Board and sets the framework for senior management. It oversees remuneration policy and its responsibilities also include:

  • making recommendations to the Board on the Company’s policy on executive Directors’ and senior management remuneration, and to oversee long-term incentive plans (including share plans);
  • ensuring remuneration is both appropriate to the level of responsibility and adequate to attract and/or retain Directors and employees of the calibre required by the Company and the Group; and
  • ensuring that executive Director remuneration is in line with current industry practice as well as in line with the internal policies for remuneration for all employees within the Group.

The Committee has presented its Remuneration Report on pages 93 to 108 of the 2026 Annual Report, which details the work it has undertaken operating under its terms of reference (which are available here and at the Company’s registered office) to discharge its responsibilities. The Remuneration Committee’s Report also explains the extent of the Board’s compliance with provisions 32 to 41 of the Code.

AIM Rule Compliance Report

The Ordinary Shares of Craneware plc are listed on the Alternative Investment Market (‘AIM’) of the London Stock Exchange and, as a result, the Company has complied with AIM Rule 31 which requires the Company to:

  • have in place sufficient systems, procedures, resources and controls to enable it to comply with the AIM Rules for Companies;
  • seek advice and guidance from its Nominated Adviser (“Nomad”) regarding its compliance with the AIM Rules for Companies whenever appropriate and take that advice into account;
  • provide its Nomad with any information it reasonably requests or requires in order for the Nomad to carry out its responsibilities under the AIM Rules for Companies and the AIM Rules for Nominated Advisers, including any proposed changes to the Board of Directors and provision of draft notifications in advance;
  • ensure that each of the Company’s Directors accepts full responsibility, collectively and individually, for its compliance with the AIM Rules for Companies; and
  • ensure that each Director discloses to the Company without delay all information which the Company needs in order to comply with the AIM Rules for Companies insofar as that information is known to the Director or could with reasonable diligence be ascertained by the Director.

In addition, Craneware plc maintains compliance with AIM Rule 26, which specifies a list of information that the Company is required to make publicly available on its website.

Approved by the Board of Directors and signed on behalf of the Board by:

Craig Preston
Chief Financial Officer
20 September 2026